NCT02355184View on ClinicalTrials.gov

An Extension of Protocol PRO 140_CD01 Study

PHASE2TerminatedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 18, 2014

Primary Completion Date

June 30, 2022

Study Completion Date

July 15, 2022

Conditions
HIVHuman Immunodeficiency Virus
Interventions
DRUG

PRO 140 350mg weekly subcutaneous (SC) injection.

CCR5 Antagonist

Trial Locations (1)

94115

CD01-Extension Investigational Site, San Francisco

Sponsors

Lead Sponsor

CytoDyn, Inc.
All Listed Sponsors
lead

CytoDyn, Inc.

INDUSTRY